Engineering of a recombinant Fab from a neutralizing IgG directed against scorpion neurotoxin AahI, and functional evaluation versus other antibody fragments

被引:18
作者
Aubrey, N
Muzard, J
Peter, JC
Rochat, H
Goyffon, M
Devaux, C
Billiald, P
机构
[1] Museum Natl Hist Nat, USM 0505, F-75231 Paris 05, France
[2] Fac Med Nord, CNRS, UMR 6560, F-13916 Marseille 20, France
[3] Inst Biol Mol & Cellulaire, CNRS, UPR 9021, F-67084 Strasbourg, France
[4] INRA, UMR Univ, Fac Pharm, F-37200 Tours, France
关键词
antivenom; Androctonus australis; antibody engineering; scorpion; toxin; immunotherapy;
D O I
10.1016/j.toxicon.2003.11.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antibody-based therapy is the only specific treatment for scorpion envenomation. However, there are still major drawbacks associated with its use; mainly because antivenoms are still prepared from immune equine serum raised against crude venoms, whereas only a limited number of neurotoxins are responsible for the lethality of the venom. Using a murine hybridoma that secretes a well-characterized neutralizing IgG directed to neurotoxins AahI and AahIII from the venom of the scorpion Androctonus australis, we constructed a recombinant Fab (rFab) fragment, which was produced and purified from transformed bacteria. It recognized toxin Aahl with a high affinity (K-D = 8.2 X 10(-11) M) equivalent to the homologous pFab prepared by papain digestion of whole IgG. Although the AahI-neutralizing capacity of protein L-purified rFab was low compared to other recombinant antibody formats (scFv and diabody) investigated in parallel, the antibody engineering approach presented here provides an innovative way to synthesize novel toxin-neutralizing molecules. It may serve as a strategy for designing a new generation of antivenoms. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 39 条
  • [1] Serotherapy in scorpion envenomation: a randomised controlled trial
    Abroug, F
    ElAtrous, S
    Nouira, S
    Haguiga, H
    Touzi, N
    Bouchoucha, S
    [J]. LANCET, 1999, 354 (9182) : 906 - 909
  • [2] Methods for the generation of chicken monoclonal antibody fragments by phage display
    Andris-Widhopf, J
    Rader, C
    Steinberger, P
    Fuller, R
    Barbas, CF
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2000, 242 (1-2) : 159 - 181
  • [3] Design and evaluation of a diabody to improve protection against a potent scorpion neurotoxin
    Aubrey, N
    Devaux, C
    Sizaret, PY
    Rochat, H
    Goyffon, M
    Billiald, P
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (03) : 617 - 628
  • [4] A recombinant scFv/streptavidin-binding peptide fusion protein for the quantitative determination of the scorpion venom neurotoxin Aahl
    Aubrey, N
    Devaux, C
    di Luccio, E
    Goyffon, M
    Rochat, H
    Billiald, P
    [J]. BIOLOGICAL CHEMISTRY, 2001, 382 (11) : 1621 - 1628
  • [5] Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
    Boder, ET
    Midelfort, KS
    Wittrup, KD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (20) : 10701 - 10705
  • [6] BOND GR, 1992, ANN EMERG MED, V21, P788, DOI 10.1016/S0196-0644(05)81022-4
  • [7] Therapeutic antibody fragments with prolonged in vivo half-lives
    Chapman, AP
    Antoniw, P
    Spitali, M
    West, S
    Stephens, S
    King, DJ
    [J]. NATURE BIOTECHNOLOGY, 1999, 17 (08) : 780 - 783
  • [8] Venoms, antivenoms and immunotherapy
    Chippaux, JP
    Goyffon, M
    [J]. TOXICON, 1998, 36 (06) : 823 - 846
  • [9] Monoclonal antibodies against the Androctonus australis hector scorpion neurotoxin I:: characterisation and use for venom neutralisation
    Clot-Faybesse, O
    Juin, M
    Rochat, H
    Devaux, C
    [J]. FEBS LETTERS, 1999, 458 (03) : 313 - 318
  • [10] Validation of biopharmaceutical purification processes for virus clearance evaluation
    Darling, A
    [J]. MOLECULAR BIOTECHNOLOGY, 2002, 21 (01) : 57 - 83